Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?

摘要: In radionuclide therapy with iodine-131 labelled pharmaceuticals, free 131I may be released and trapped by the thyroid, causing an undesirable radiation burden. To prevent this, stable iodide such as potassium (KI) can given to saturate thyroid before is administered. The guidelines of European Association Nuclear Medicine do not, however, recommend special precautions when administering 131I-lipiodol for hepatocellular carcinoma. Nevertheless, some authors have reported uptake in a consequence therapy. this study, influence prophylactic KI on dose (MIRD dosimetry) was prospectively investigated. slow bolus selectively proper hepatic artery or hyperselectively right and/or left artery. Patients were randomised into two groups. One group received 100 mg per day starting 2 days administration continuing until weeks after (KI group; n=31), while other no (non-KI n=37). Thyroid measured scintigraphically percentage administered activity 7 (n=68 treatments). absorbed assessed scintigraphy 14 using mono-exponential fitting model MIRD dosimetry (n=40 mean 1,835 MBq volume (n=17) 4 (n=51) ml. lower group, being 0.23%±0.06% injected (n=31) compared 0.42%±0.20% non-KI (n=37); 5.5±1.6 Gy (n=19) versus 11.9±5.9 (n=21). These differences statistically significant (P 0.1). associated generally low that significantly decreased premedication. Given cost very good tolerance treatment, we believe use should recommended majority patients.